Broadfoot Jill Marie 4

What Happened

• Jill Broadfoot, Chief Financial Officer of aTYR Pharma (ATYR), had 3,750 restricted stock units (RSUs) convert into 3,750 shares on Feb 3, 2026. Following the vesting, she sold 1,558 shares in an open-market sale on Feb 4, 2026 at $0.98 per share, generating $1,521. The filings also show the RSU conversion entries associated with the vesting event.

Key Details

• Dates and prices:
  • Feb 3, 2026: 3,750 RSUs vested and converted into 3,750 common shares (conversion reported as derivative exercise/conversion).
  • Feb 4, 2026: Open-market sale of 1,558 shares at $0.98/share for proceeds of $1,521.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnotes of note:
  • RSUs were granted Feb 3, 2022 and convert one-for-one to common stock.
  • The RSUs vest in four equal annual installments beginning Feb 3, 2023 and fully vest Feb 3, 2026; they have change-of-control acceleration protection.
  • The sale was made to satisfy tax withholding obligations in connection with the partial vesting.
• Timeliness: Form was filed Feb 4, 2026 for transactions occurring Feb 3–4, 2026 (appears timely under Section 16 reporting rules).

Context

• This was primarily an award/vesting event (not a cash purchase). The subsequent sale was a routine tax-withholding sale rather than a discretionary, market-timing sale; such sales are commonly used to cover tax liabilities when RSUs vest. The filing shows conversion of RSUs to shares (derivative conversion) and a follow-up open-market sale of a portion of the vested shares.